David A Hamilton, Mohindar M Karunakaran, Seth B Coffelt
In this issue of Cancer Cell, Ng et al. characterize and leverage cytotoxic γδ T cells in small cell lung cancer to overcome unsuccessful checkpoint blockade immunotherapy. Engaging Vδ2+ cells with a bispecific T cell engager (BiTE) bypasses the challenge of low MHC-I expression and ineffective CD8+ T cells.